Sirtris Pharmaceuticals to Present at Molecular Genetics of Aging Meeting at Cold Spring Harbor Laboratory on October 4-8th, 2006

Cambridge, MA –October 3rd, 2006 -- Sirtris Pharmaceuticals, the leading sirtuin therapeutics company, announced today that it will be presenting at the Cold Spring Harbor Laboratory Molecular Genetics of Aging meeting. Jill Milne, Ph.D., Senior Director of Biology at Sirtris, will present “SIRT1 Activation: A Novel Mechanism for Treating Age-Related Diseases” and discuss the Company’s strategy for discovering and developing first in class therapeutics that modulate sirtuins, a recently discovered family of enzymes that promote healthy cellular function to treat diseases of aging, such as diabetes and neurological diseases.

“The Cold Spring Harbor Molecular Genetics of Aging meeting is one of the most important academic aging conferences, and Sirtris’ participation is a testament to the industry-leading research and development we are contributing to the field,” said Mike Jirousek, Ph.D., Senior Vice President of Research at Sirtris Pharmaceuticals.

About Sirtuins

Sirtuins are a recently discovered family of enzymes that promote normal cellular function. In particular, sirtuins improve the function of mitochondria which generate energy in cells. When organisms face adversity, sirtuins are activated as part of a natural process that maintains healthy function.

Therefore, sirtuins are attractive drug targets which may be therapeutically beneficial for diseases in which mitochondria are dysfunctional, often observed in diseases of aging. These diseases include metabolic diseases such as Type 2 Diabetes, neurological diseases, and other mitochondrial disorders. Sirtuin therapeutics offer the potential for a novel class of drugs that can treat significant diseases of aging in a new way.

About Sirtris Pharmaceuticals

Sirtris Pharmaceuticals is a biopharmaceutical company developing novel therapeutics that modulate sirtuins. Sirtris has the dominant sirtuin intellectual property estate and know-how with a comprehensive suite of reagents, proprietary assays, transgenic animal models, and biomarkers. Sirtris is building a robust pipeline of therapeutics for diseases of aging in the areas of metabolic and neurological diseases.

Sirtris Pharmaceuticals was founded in 2004 by Rich Aldrich, Richard Pops, Paul Schimmel, David Sinclair and Christoph Westphal and has raised a total of $82 million since inception from investors including: Bessemer Venture Partners, Cardinal Partners, Cargill Ventures, Genzyme Ventures, Novartis Bioventures Fund, Polaris Venture Partners, QVT Fund LP, Skyline Ventures, The Wellcome Trust, Three Arch Partners, and TVM Capital. The company’s headquarters are in Cambridge, Massachusetts. For additional information, please visit http://www.sirtrispharma.com. Email To : Email From : Message : Submit Cancel